Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsharvard pilgrim prior auth specialty drug policy |…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    Tufts Medicare Preferred Prior Authorization Medical Necessity Guidelines (partial drug list)

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists products subject to prior authorization with indication-specific medical necessity requirements, prescriber restrictions, coverage durations, and prerequisite therapy notes for covered members and prescribing providers.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyTufts Medicare Preferred Prior Authorization Medical Necessity Guidelines (partial drug list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documented diagnosis, required specialist prescriber attestation (when specified), and supporting clinical information per product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+documented drug entries (excerpt)
    2 yearstypical coverage duration
    severalspecialist prescriber required
    someprerequisite Part D drug required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1Part B vs Part D notes

    Product-Specific Coverage Criteria

    Product-specific initial coverage criteria (partial)

    Examples of product-specific medical necessity criteria as stated in the document (partial list):

    Abilify Mycite: Member has a documented diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia AND documentation of worsening symptoms with oral aripiprazole

    Prescribing physician must be a psychiatrist; coverage duration 2 years; prerequisite Part D drug required.

    Benlysta (belimumab): Member has documented diagnosis of active, autoantibody-positive systemic lupus erythematosus (SLE) or active lupus nephritis AND is concurrently taking standard therapy (eg, antimalarials, corticosteroids, or immunosuppressives)

    Will not be approved as monotherapy or for autoantibody-negative members; prescriber must be a nephrologist or rheumatologist; coverage duration 2 years.

    Armodafinil/Modafinil: Member has a documented diagnosis of narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift-work sleep disorder

    Coverage will not be approved for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis; coverage duration 2 years.

    Caplyta: Member has a documented diagnosis of schizophrenia, bipolar depression, or major depressive disorder (when used as adjunctive therapy with antidepressants)

    Prescribing physician must be a psychiatrist; coverage duration 2 years.

    Sample product criteria

    Examples of product-specific required criteria (selected entries from excerpt):

    Cabozantinib (Cometriq)/Caprelsa-type medullary thyroid cancer agents: Member must have a documented diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease

    Prescribing physician must be an endocrinologist or oncologist; coverage duration 2 years.

    Cayston

    Cayston: Diagnosis of cystic fibrosis AND evidence of Pseudomonas aeruginosa in the lungs

    Coverage duration 2 years.

    Dupixent

    Dupixent indications: Covered for specified indications when indication-specific requirements are met (eg, atopic dermatitis with trial/failure of topical agents; asthma with eosinophilic phenotype or oral steroid dependence; CRSwNP inadequately controlled; prurigo nodularis; eosinophilic esophagitis; COPD with eosinophilic phenotype; bullous pemphigoid; allergic fungal rhinosinusitis)

    Prescribed by or in consultation with relevant specialists; coverage duration 2 years; excluded for acute bronchospasm/status asthmaticus.

    Selected product-specific initial criteria

    Products with indication- or diagnosis-specific authorization conditions (examples from this excerpt).

    Everolimus/related products (examples): Member must have a documented diagnosis relevant to the specific indication (eg, partial-onset seizures associated with TSC; SEGA associated with TSC and not a candidate for surgical resection)

    Prescriber must be a neurologist or oncologist depending on product; coverage duration typically 2 years.

    RET-targeted therapy

    RET fusion-positive cancers (Gavreto example).

    Gavreto: Member must have metastatic RET fusion-positive NSCLC OR advanced/metastatic RET fusion-positive thyroid cancer refractory to radioactive iodine when appropriate

    Prescribing physician must be an oncologist; coverage duration 2 years.

    EGFR mutation-targeted therapy

    EGFR mutation-specific therapy eligibility (Gefitinib example).

    Gefitinib: Documented diagnosis of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations

    Prescribing physician must be an oncologist; coverage duration 2 years.

    Jaypirca — indication-specific criteria

    Covered when ALL of the following are met for Jaypirca (example entry in these chunks):

    Jaypirca: chronic GVHD/myelofibrosis/PV indications: Member has a documented diagnosis of chronic GVHD after failure of one or two lines of systemic therapy OR intermediate/high-risk myelofibrosis (primary, post-PV, post-ET) OR polycythemia vera with inadequate response/contraindication/intolerance to hydroxyurea

    For myelofibrosis subsequent authorization requires documentation of spleen size reduction or symptomatic improvement; prescribed by or in consultation with an oncologist.

    Jubbonti — MCL and CLL/SLL

    Covered when ALL of the following are met for Jubbonti:

    Jubbonti indications (MCL or CLL/SLL): 1) Relapsed/refractory mantle cell lymphoma with at least two prior systemic therapies including a BTK inhibitor OR 2) Chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with a covalent BTK inhibitor

    Prescribed by or in consultation with an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Jynarque — liver monitoring and duration-based schedule

    Covered when ALL of the following are met for Jynarque (tolvaptan):

    Jynarque initial ADPKD: Diagnosis of rapidly progressing ADPKD AND either (a) patient has received Jynarque ≤18 months AND ALT, AST, and bilirubin measured prior to initiation, at 2 and 4 weeks after initiation, then monthly for first 18 months OR (b) patient has received Jynarque >18 months AND ALT, AST, and bilirubin measured at least every 3 months

    Patient must not have history of significant liver impairment or injury (excluding uncomplicated polycystic liver disease); coverage duration 1 year.

    Kalydeco — genotype and age requirements

    Covered when ALL of the following are met for Kalydeco (ivacaftor):

    Kalydeco CF criteria: Documented diagnosis of cystic fibrosis AND presence of at least one CFTR mutation responsive to ivacaftor based on clinical and/or in vitro assay data; if genotype unknown, an FDA-cleared CF mutation test should be used with verification sequencing when recommended

    Granules: patient age ≥1 month; coverage duration 2 years; patients homozygous for F508del are not effective for Kalydeco (exclusion).

    Kineret — RA and NOMID criteria

    Covered when ALL of the following are met for Kineret (anakinra):

    Kineret RA initial: Diagnosis of moderately to severely active rheumatoid arthritis AND either (a) trial and failure, contraindication, or intolerance to two of the listed alternatives (eg, Enbrel, a formulary adalimumab product, Orencia, Rinvoq, Xeljanz) OR (b) attestation that trials are inappropriate OR continuation of prior therapy

    Prescribed by or in consultation with a rheumatologist for RA initial; NOMID requires genetic confirmation or clinical criteria plus elevated acute phase reactants.

    Krazati — KRAS G12C-mutated cancers

    Covered when ALL of the following are met for Krazati (adagrasib) in NSCLC or CRC:

    Krazati NSCLC: Diagnosis of locally advanced or metastatic NSCLC AND tumor is KRAS G12C-mutated AND patient has received at least one prior systemic therapy

    Prescribed by or in consultation with an oncologist; coverage duration 2 years.

    Krazati CRC: KRAS G12C-mutated locally advanced or metastatic colorectal cancer AND prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND when used, combination with cetuximab is specified

    Prescribed by or in consultation with an oncologist; coverage duration 2 years.

    Livtencity — refractory CMV

    Covered when ALL of the following are met for Livtencity (maribavir) in post-transplant CMV:

    Livtencity refractory CMV: Member ≥35 kg with documented post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet

    Coverage duration 2 years; prescribed by or in consultation with transplant specialist as applicable.

    Lonsurf — colorectal and gastric cancer prior therapies

    Covered when ALL of the following are met for Lonsurf (trifluridine/tipiracil) indications:

    Lonsurf mCRC: Metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biologic, and if RAS wild-type, an anti-EGFR therapy

    Prescribing physician must be an oncologist; coverage duration 2 years.

    Lonsurf gastric/GEJ adenocarcinoma: Metastatic gastric or gastroesophageal junction adenocarcinoma with at least two prior lines of chemotherapy including a fluoropyrimidine and a platinum, and either a taxane or irinotecan, and if appropriate, HER2-targeted therapy

    Prescribing physician must be an oncologist; coverage duration 2 years.

    Lynparza — BRCA/HRR-associated indications and maintenance settings

    Covered when ALL of the following are met for Lynparza (olaparib):

    Lynparza breast cancer: Deleterious or suspected deleterious germline BRCA-mutated HER2-negative metastatic breast cancer treated with chemotherapy in relevant settings OR high-risk early breast cancer treated with neoadjuvant or adjuvant chemotherapy

    Prescribing physician must be an oncologist; prerequisite Part D drug required for tabs; coverage duration 2 years.

    Lynparza ovarian cancer maintenance: Maintenance treatment for deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian/fallopian tube/primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy OR maintenance in combination with bevacizumab for HRD-positive disease in complete/partial response OR maintenance for recurrent disease in complete/partial response to platinum-based chemotherapy

    Coverage duration 2 years.

    Lynparza pancreatic cancer: Deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma with no disease progression after ≥16 weeks of first-line platinum-based chemotherapy

    Coverage duration 2 years.

    Lynparza — Indication-specific criteria

    Lynparza — Covered when ALL of the following are met for the listed indications:

    Indications: Breast, ovarian, pancreatic, and prostate cancer indications when deleterious or suspected deleterious BRCA/HRR mutations and prior therapy and response criteria as specified in product entry are metas stated

    Prescribing physician must be an oncologist; see product entry for full indication-specific requirements and prerequisite Part D drug status.

    Lytgobi — Indication-specific criteria

    Lytgobi — Covered when ALL of the following are met:

    Lytgobi indication: Documented diagnosis of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements

    Prescribed by or in consultation with an oncologist; coverage duration 2 years.

    PAH/CTEPH agents — Indication-specific criteria

    PAH and related agents — Covered when ALL of the following are met:

    PAH indications: Documented diagnosis of pulmonary arterial hypertension confirmed by right heart catheterization OR documented persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable disease

    Prescriber must be a cardiologist or pulmonologist; coverage duration 2 years.

    Mekinist — Indication-specific criteria and exclusions

    Mekinist (trametinib) — Covered when ALL of the following are met:

    Mekinist single agent: Single-agent use: documented unresectable or metastatic melanoma with BRAF V600E or V600K mutations

    Exclusion: will not be approved as single agent for members who have received prior BRAF-inhibitor therapy; prescriber must be an oncologist; coverage duration 2 years.

    Mekinist with Tafinlar: In combination with dabrafenib (Tafinlar): documented diagnoses including unresectable/metastatic melanoma with BRAF V600E or V600K, melanoma with node involvement following resection, metastatic NSCLC with BRAF V600E, locally advanced/metastatic anaplastic thyroid cancer with BRAF V600E without satisfactory locoregional options, unresectable/metastatic solid tumors with BRAF V600E progressed after prior treatment, low grade glioma with BRAF V600E requiring systemic therapy

    Prescriber must be an oncologist; coverage duration 2 years.

    Orkambi (CF)

    Orkambi (excerpted rules): Covered when ALL of the following are met

    Orkambi initial criteria: Member has documented diagnosis of cystic fibrosis AND member is homozygous for the F508del mutation

    Coverage duration 2 years; prescriber or consultation as specified.

    Otezla (Psoriasis/PsA/Behcet's)

    Otezla (excerpted rules): Covered when ALL of the following are met

    Otezla indications: Member has diagnosis of psoriatic arthritis OR plaque psoriasis with prior topical therapy failure OR Behcet's disease with active oral ulcers

    Prescribed by or in consultation with a dermatologist or rheumatologist; coverage duration 2 years; prerequisite Part D drug required.

    Pemazyre (FGFR-altered cancers)

    Pemazyre (excerpted rules): Covered when ALL of the following are met

    Pemazyre indications: Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion AND previously treated OR relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Praluent / Repatha (Hyperlipidemia/ASCVD)

    Praluent/Repatha (PCSK9 inhibitors): Covered when ALL of the following are met

    PCSK9 inhibitors criteria: Member has elevated LDL-C while on high-intensity statin OR has statin contraindication/intolerance; AND member has documented ASCVD OR HeFH (confirmed by genetic testing or clinical criteria) OR HoFH (confirmed)

    Coverage duration 2 years; prerequisite Part D drug required.

    Rezdiffra (MASH/NASH)

    Rezdiffra (MASH/NASH): Covered when ALL of the following are met

    Rezdiffra initial criteria: Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis; fibrosis stage F2 or F3 confirmed by specified serum and imaging biomarkers or liver biopsy; AND presence of ≥1 metabolic risk factor (eg, type 2 diabetes, hypertension, obesity)

    Prescribed by or in consultation with a gastroenterologist or hepatologist; coverage duration 2 years; reauthorization requires positive response and no progression to cirrhosis.

    Rezlidhia (IDH1-mutant AML)

    Rezlidhia: Covered when ALL of the following are met

    Rezlidhia criteria: Relapsed or refractory acute myeloid leukemia with documentation of a susceptible IDH1 mutation

    Prescribed by or in consultation with an oncologist or hematologist; coverage duration 2 years.

    Rubraca (BRCA-mutant ovarian cancer)

    Rubraca (excerpted): Covered when ALL of the following are met

    Rubraca maintenance criteria: Deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy

    Not approved concurrently with other chemotherapy agents; prescriber must be an oncologist; coverage duration 2 years.

    Rydapt — AML (FLT3+), ASM, MCL

    Rydapt (example): Covered when ALL of the following are met

    Rydapt initial combination therapy: Member has documented diagnosis of acute myeloid leukemia that is FLT3 mutation-positive AND Rydapt is being used as first-line therapy in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation

    Prescribing physician must be a hematologist, oncologist, or allergist; coverage duration 2 years; Rydapt not approved as single-agent induction therapy for AML.

    Stelara — required trial of preferred agents

    Stelara: Covered when ALL of the following are met

    Stelara indications: Member has documented diagnosis appropriate to indication (eg, moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis) AND member has trial, intolerance, or contraindication to Yesintek or Steqeyma

    Prescriber must be or consult a dermatologist, gastroenterologist, or rheumatologist; coverage duration 2 years.

    Tibsovo — IDH1-mutated disease

    Tibsovo: Covered when ALL of the following are met

    Tibsovo indications: Relapsed or refractory AML with susceptible IDH1 mutation OR newly diagnosed AML with susceptible IDH1 mutation when monotherapy or with azacitidine in patients ≥75 years or ineligible for intensive induction OR cholangiocarcinoma previously treated OR relapsed/refractory MDS

    Prescribing physician must be a hematologist or oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Transmucosal Immediate-Release Fentanyl — cancer-related breakthrough pain

    TIRF products: Covered when ALL of the following are met

    TIRF (fentanyl transmucosal): Used for management of breakthrough pain in adult cancer patients who are already receiving and are tolerant to around-the-clock opioid therapy for persistent cancer pain; patients must remain on around-the-clock opioids when taking transmucosal fentanylopioid tolerance defined in documentation (examples provided)

    Not covered for any non-cancer pain indication; approvable for pediatric patients ≥16 years for lozenges; prescriber must be an oncologist or pain management specialist; coverage duration 2 years.

    Trikafta — cystic fibrosis

    Trikafta: Covered when ALL of the following are met

    Trikafta initial therapy: Diagnosis of cystic fibrosis AND patient has at least one F508del mutation OR a CFTR mutation responsive based on clinical and/or in vitro dataage-specific formulation limits: granules for 2 to <6 years; tablets for ≥6 years

    Prescribed by or in consultation with a pulmonologist or CF care center specialist; reauthorization requires positive clinical response (eg, improved ppFEV1 or fewer pulmonary exacerbations); coverage duration 2 years.

    Cystic Fibrosis (example: granule vs tablet age limits and genotype requirement)

    Covered when ALL of the following are met

    CF initial criteria: Diagnosis of cystic fibrosis AND at least one of: F508del mutation OR a CFTR mutation responsive based on clinical/in vitro data; age limits: granule packets 2 to <6 years, tablets ≥6 years; prescribed by or in consultation with a pulmonologist or CF care center specialist

    Reauthorization requires positive clinical response (eg, improved ppFEV1 or decreased pulmonary exacerbations); coverage duration 2 years.

    Tukysa (PIK3CA/AKT1/PTEN-altered HR+/HER2- breast cancer)

    Covered when ALL of the following are met

    Tukysa initial criteria: Documented diagnosis of locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN alterations AND to be taken with fulvestrant; disease progression after at least one endocrine-based regimen in metastatic setting OR recurrence on/within 12 months of completing adjuvant therapy

    Prescribed by an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Tukysa alternate/other (Tukysa prescriber restriction) and Turalio TGCT

    Tukysa prescriber requirement: Prescribing physician must be an oncologist
    Turalio initial criteria: Documented diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) with severe morbidity or functional limitations not amenable to improvement with surgery

    Coverage duration 2 years.

    Ubrelvy and related rheumatologic/IL D/autoimmune agent criteria

    RA and related indications (example entry): For RA initial: diagnosis of moderately to severely active RA AND either trial and failure/contraindication/intolerance to two listed agents (eg, etanercept, formulary adalimumab, abatacept, upadacitinib, tofacitinib) OR attestation that trials are inappropriate OR continuation of prior therapy

    Prescriber restriction: rheumatologist consultation; coverage duration 1 year; reauthorization requires demonstration of positive clinical response.

    SSc-ILD: Diagnosis of systemic sclerosis-associated interstitial lung disease documented by exclusion of other ILD causes AND HRCT or biopsy patterns consistent with SSc-ILD

    Prescribed by pulmonologist or rheumatologist; coverage duration 1 year; prerequisite Part D drug required.

    Ubrelvy (migraine)

    Ubrelvy initial criteria: Documented diagnosis of migraine AND inadequate response, intolerance, or contraindication to at least one triptan medication

    Coverage duration 2 years; prerequisite Part D drug required.

    Ustekinumab (multiple indications)

    Ustekinumab criteria: Indication-specific documented diagnoses (eg, moderate-to-severe Crohn's, plaque psoriasis with failure/intolerance to listed topical/systemic agents, psoriatic arthritis, moderate-to-severe ulcerative colitis) AND trial/intolerance/contraindication to Yesintek or Steqeyma

    Prescriber restriction: dermatologist, gastroenterologist or rheumatologist; coverage duration 2 years; prerequisite Part D drug required.

    Oncology products (Vanflyta, Venclexta, Vitrakvi, Vizimpro, Vonjo, etc.)

    Vanflyta: Documented diagnosis of newly diagnosed AML that is FLT3-ITD positive

    Prescriber oncologist/hematologist; coverage duration 2 years; no prerequisite Part D drug required.

    Venclexta (AML/CLL/SLL): AML: used as first-line with azacitidine/decitabine/low-dose cytarabine in patients ≥75 years or with comorbidities precluding intensive induction; CLL/SLL: documented diagnosis as indicated

    Prescriber hematologist/oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Vitrakvi: Documented metastatic or unresectable NTRK gene fusion-positive solid tumor with no known acquired resistance mutation and no satisfactory alternative treatments or progressed following treatment

    Prescriber oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Voquezna (Helicobacter pylori and erosive esophagitis indications)

    Voquezna H. pylori: Diagnosis of Helicobacter pylori infection AND trial and failure/intolerance/contraindication to bismuth quadruple therapy

    NERD and erosive esophagitis criteria and duration vary by product form; prerequisite Part D drug required.

    Voriconazole and Vosevi

    Voriconazole INJ: Documented diagnosis of serious fungal infection (eg, invasive aspergillosis, candidemia, CNS infection) or infection caused by Scedosporium or Fusarium refractory/intolerant to other therapy

    Coverage duration 2 years.

    Vosevi: Criteria applied consistent with current AASLD-IDSA guidance for hepatitis C treatment; prescriber must be gastroenterologist/hepatologist/infectious disease specialist

    Coverage duration aligned with guidance; no prerequisite Part D drug required.

    Vowst (recurrent C. difficile)

    Vowst criteria: Diagnosis of recurrent Clostridioides difficile infection AND completion of oral vancomycin or fidaxomicin 2–4 days prior to initiating Vowst

    Prescribed by or in consultation with a gastroenterologist or infectious disease specialist; coverage 14 days; prerequisite Part D drug required.

    Vyndamax (ATTR-CM)

    Vyndamax initial criteria: Documented transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) by TTR mutation or tissue biopsy or supportive imaging plus absence of light-chain amyloidosis AND documentation of NYHA Functional Class I–III heart failure

    Prescriber cardiologist for initial and reauthorization; coverage for plan year; reauth requires ongoing NYHA I–III.

    Wyost (denosumab) and specified indications

    Wyost coverage conditions: Coverage authorized if one of: (1) prevention of skeletal-related events in multiple myeloma or bone metastases from solid tumors; (2) treatment for unresectable giant cell tumor of bone (GCTB) or when surgery likely to cause severe morbidity; (3) treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy

    Coverage duration 2 years; prerequisite Part D drug required.

    Wyost specified indications: Member has documented diagnosis of von Hippel-Lindau disease requiring therapy for associated RCC, CNS hemangioblastomas, or pancreatic NETs not requiring immediate surgery OR advanced RCC following PD-1/PD-L1 inhibitor and VEGF-TKI OR locally advanced/unresectable/metastatic PPGL

    Prescribing physician must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Xalkori and Xdemvy — oncologic and ophthalmic indications

    Xalkori/Xdemvy (examples) covered when specific tumor biomarkers or diagnoses are documented

    Xalkori criteria: Documented ALK-positive metastatic NSCLC OR ROS1-positive tumors OR relapsed/refractory ALCL that is ALK-positive OR unresectable/recurrent/refractory IMT that is ALK-positive

    Prescribing physician must be an oncologist; biomarker documentation required; coverage duration 2 years.

    Xdemvy criteria: Documented diagnosis of Demodex blepharitis

    Medication must be prescribed by or in consultation with an ophthalmologist or optometrist; coverage duration 2 years.

    Tofacitinib family — inflammatory disease criteria

    Tofacitinib/Xeljanz family indications with stepped requirements

    Rheumatologic indications: Ankylosing spondylitis, RA, PJIA, psoriatic arthritis require diagnosis and inadequate response or intolerance to one or more TNF inhibitors (and RA/PJIA require trial/failure of one conventional therapy)

    Prescribed by or in consultation with relevant specialist; coverage duration 2 years; prerequisite Part D drug required.

    UC indication: Moderately to severely active ulcerative colitis requires inadequate response or intolerance to specified prior therapy per product entry

    Prescribed by or in consultation with gastroenterologist or rheumatologist; coverage duration 2 years.

    Xermelo — carcinoid syndrome diarrhea with SSA

    Xermelo coverage requirements

    Xermelo for carcinoid syndrome diarrhea: Documented carcinoid syndrome diarrhea inadequately controlled by somatostatin analog therapy AND Xermelo is being used in combination with an SSA

    Prescribing physician must be a gastroenterologist, hematologist, or oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Xpovio — relapsed/refractory hematologic malignancy criteria

    Xpovio and other oncology agents — relapsed/refractory criteria

    Xpovio multiple myeloma: In combination with dexamethasone: documented relapsed/refractory multiple myeloma AND at least four prior therapies AND disease refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody

    Prescriber must be a hematologist/oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Xpovio DLBCL: For relapsed/refractory diffuse large B-cell lymphoma: documented diagnosis and at least two lines of systemic therapy

    Prescriber hematologist/oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Xtandi — prostate cancer indications

    Xtandi indications

    Xtandi criteria: Documented non-metastatic castration-resistant prostate cancer OR metastatic hormone-sensitive prostate cancer when used in combination with docetaxel

    Prescriber must be an oncologist or urologist; coverage duration 2 years.

    Biologics — gastroenterology and dermatology indications

    Biologics for Crohn's, psoriasis, psoriatic arthritis, UC

    Biologic criteria: Diagnosis of respective condition (eg, moderately to severely active Crohn's disease or ulcerative colitis, moderate-to-severe plaque psoriasis, active psoriatic arthritis) AND failure or intolerance to listed topical or conventional agents

    Prescriber restriction to dermatology/gastroenterology/rheumatology; coverage duration 2 years; prerequisite Part D drug required.

    Zejula — ovarian cancer maintenance

    Zejula maintenance/recurrence criteria

    Zejula criteria: Advanced or recurrent epithelial ovarian/fallopian tube/primary peritoneal cancer in complete or partial response to platinum-based chemotherapy OR recurrent disease with deleterious/suspected deleterious germline BRCA mutation in complete or partial response to platinum-based chemotherapy

    Prescribing physician must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Zelboraf and Zolinza — specified hematology/oncology indications

    Zelboraf and Zolinza indications

    Zelboraf criteria: Erdheim-Chester Disease with BRAF V600 mutation OR unresectable/metastatic melanoma BRAF V600E mutation-positive

    Prescriber must be an oncologist or hematologist; coverage duration 2 years.

    Zolinza criteria: Cutaneous T-cell lymphoma with progressive, persistent or recurrent disease and documented current or prior treatment or failure with at least two systemic chemotherapeutic agents

    Prescribing physician must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Ztalmy — CDKL5 seizure disorder

    Ztalmy coverage

    Ztalmy criteria: Diagnosis of seizures associated with CDKL5 deficiency disorder (CDD)

    Prescriber must be or consult a neurologist; coverage duration 2 years.

    Zydelig and Zykadia — hematology/oncology criteria

    Zydelig and Zykadia entries

    Zydelig criteria: Relapsed chronic lymphocytic leukemia being used in combination with rituximab

    Prescribing physician must be a hematologist or oncologist; coverage duration 2 years.

    Zykadia criteria: Documented ALK-positive metastatic non-small cell lung cancer

    Prescribing physician must be an oncologist; coverage duration 2 years.

    Armodafinil and modafinil are covered only for their labeled sleep disorders (for example, narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift-work sleep disorder). Coverage will not be approved for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis, and requests lacking an approved indication may be denied.

    Dupixent is subject to indication-specific documentation and prior authorization. Requests for Dupixent submitted for the relief of acute bronchospasm or status asthmaticus will not be approved; approvals are limited to the chronic, labeled indications when the product-specific criteria (including prerequisite therapies and specialist consultation where required) are met.

    Icatibant is covered for hereditary angioedema when policy criteria are met, but coverage will not be approved for members with acquired angioedema or for members who are concurrently taking an ACE inhibitor.

    Iclusig (ponatinib) has product-specific limits and will not be approved for members with newly diagnosed chronic phase CML; authorization is reserved for the labeled indications and scenarios such as T315I-positive disease or resistant/accelerated/blast phases per the criteria.

    Increlex (mecasermin) is limited to primary severe IGF-1 deficiency as defined in the policy. Coverage will not be authorized for secondary forms of IGF-1 deficiency (for example, due to growth hormone deficiency, malnutrition, hypothyroidism, or chronic steroid therapy).

    Kalydeco (ivacaftor) requires documentation of a CFTR mutation responsive to the drug. The policy notes that Kalydeco is not effective in patients homozygous for the F508del CFTR mutation; such patients are excluded from coverage for that indication.

    Mekinist (trametinib) may be approved per the listed oncologic indications; however, it will not be approved as a single agent for members who have received prior BRAF‑inhibitor therapy. Combination use (e.g., with dabrafenib) is subject to the product-specific criteria and prescriber specialty requirements.

    Quinine sulfate is limited to labeled infectious disease indications; coverage will not be approved for the treatment or prevention of nocturnal leg cramps.

    Rubraca (rucaparib) is covered for BRCA‑associated ovarian and selected prostate indications when criteria are met, but will not be approved for concurrent use with other chemotherapy agents (concurrent cytotoxic chemotherapy is an explicit exclusion).

    Rydapt (midostaurin) is authorized for FLT3‑positive AML in combination with standard induction/consolidation regimens and other labeled hematologic indications as specified. Requests for Rydapt as single‑agent induction therapy for AML will not be approved.

    Tadalafil is not covered for the treatment of erectile dysfunction under this benefit. The policy explicitly states that Tadalafil is excluded from coverage for erectile dysfunction; approvals may be considered for other labeled indications (for example, BPH) only when the product‑specific criteria are satisfied.

    Transmucosal immediate‑release fentanyl (TIRF) products are limited to management of breakthrough pain in opioid‑tolerant cancer patients. The policy specifies that TIRF products will not be covered for any non‑cancer pain indication and requires documentation of opioid tolerance and ongoing around‑the‑clock opioid therapy for approval.

    (Duplicate entry noted.) Rydapt will not be approved as single‑agent induction therapy for AML; authorization is limited to combination use with standard induction/consolidation regimens and other labeled indications per the criteria.

    Several products in this segment include individual exclusions or indication limits. Examples include exclusions for off‑label uses (noted as N/A in many entries), explicit product‑level exclusions (for example, Kalydeco non‑effectiveness in F508del homozygotes, Rubraca not for concurrent chemotherapy), and mutation‑ or setting‑based limits. Requests for uses explicitly excluded in the product‑specific sections may be denied.

    Off‑label uses are commonly listed as N/A in the product entries in this excerpt; where explicit exclusion criteria apply they are documented per product. For many products the policy therefore treats off‑label indications as not covered unless the specific product criteria indicate otherwise.

    Zelboraf (vemurafenib) requires documentation of a BRAF V600 mutation for covered indications; the policy clarifies that Zelboraf is not indicated for treatment of patients with wild‑type BRAF melanoma and such requests will not meet medical necessity.

    Coverage assignment between Medicare Part B and Part D depends on the drug's use and setting. The policy states that this determination may require submission of information describing how and where the drug will be used to determine whether the drug is billed under Part B or Part D.

    Use of drugs for conditions explicitly excluded in the product‑specific sections (for example, generalized fatigue or jet lag for modafinil) should not be submitted as medically necessary; such requests are noted as exclusions and are subject to denial.

    Reminder: Kalydeco is not effective for patients who are homozygous for the F508del CFTR mutation; requests for ivacaftor in that genotype do not meet medical necessity under this policy and will be excluded.

    Reminder: Tadalafil is explicitly excluded from coverage for the treatment of erectile dysfunction under this benefit; requests for ED should be considered not medically necessary per the policy exclusion.

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required — submit diagnosis and supporting clinical information

    Prior authorization is required for coverage of the products listed in this policy; submit the product-specific prior authorization request including the diagnosis and any required supporting clinical information. Many products specify a 2-year coverage duration when authorized.

    • Include the documented diagnosis required by the product entry (e.g., CF, PAH, BRCA/HRR-mutated cancer).
    • Provide supporting clinical information and any required mutation/genotype or test results as specified for the product.
    • Note prescriber specialty when the product requires a specialist (e.g., oncologist, pulmonologist, cardiologist).
    Prior Authorization

    Prior authorization required for listed specialty drugs — supply required specialty documentation

    Submit a prior authorization request for each specialty drug listed; include the indication-specific documentation, prescriber specialty attestation when required, and evidence of prerequisite therapies or part‑D drug trials if the product's criteria state so.

    Initial Therapy Requirements

    Continuation / Reauthorization Requirements

    Step Therapy and Prerequisite Drug Requirements

    RequirementWhat provider must document
    Document prior use or intolerance of specified conventional or targeted therapies when required per productMedical record evidence of prior trial(s) (dates, drug names, doses) or documentation of contraindication/intolerance or clinician attestation that trials are inappropriate
    Indication / Product examplesRequired prior treatment trial
    Plaque psoriasis / Psoriatic arthritis / Ankylosing spondylitis (biologics)Trial and failure, contraindication, or intolerance to specified topical or conventional therapies (e.g., topical corticosteroids, vitamin D analogs, tazarotene) and for some indications failure of one or more TNF inhibitors as specified
    Ulcerative colitis / Crohn's disease biologicsInadequate response or intolerance to one or more TNF inhibitors, or if TNF blockers clinically inadvisable, trial of at least one approved systemic therapy as specified
    Product examplesPrerequisite Part D drug required?
    Genotropin / Gomekli (examples in excerpt)Some entries state 'Criteria DOES require use of a prerequisite Part D drug' while others explicitly 'DOES NOT require' — product-level language must be followed
    Nexletol / Nexlizet / PCSK9-type entriesExample entries indicate 'Criteria DOES require use of a prerequisite Part D drug'
    RequirementAcceptable documentation
    Document trial(s) of listed agents or attestation that trials are inappropriateRecords showing prior medication use and outcome (TF/C/I), or clinician attestation in chart noting why trials are clinically inappropriate or unsafe
    Example: RA prior therapy requirementTrial and failure, contraindication, or intolerance to two listed alternatives (e.g., Enbrel, adalimumab, Orencia, Rinvoq, Xeljanz) OR signed attestation that trials are inappropriate
    Products citing prerequisite Part D drugPolicy note
    Lynparza (tabs)Entry indicates 'Criteria DOES require use of a prerequisite Part D drug' for specified indications
    Stivarga / other examplesSeveral product entries in the excerpt explicitly require prior Part D therapy; follow the product-specific line-item language
    Indications (examples)Step requirement
    Rheumatologic indications (RA, PsA, ankylosing spondylitis)Trial and failure of conventional DMARD(s) and, depending on indication, failure/inadequate response to one or more TNF inhibitors or other specified biologics prior to coverage
    Crohn's disease / Ulcerative colitisRequire inadequate response or intolerance to one or more TNF inhibitors (or other systemic therapies if TNF inhibitors are inadvisable) before approval
    ScopeRequirement
    cGVHD, other hematologic/autoimmune indicationsPrior systemic therapy failure required (e.g., Rezurock: trial and failure of two or more systemic therapy lines for cGVHD) per product criteria
    Rinvoq / similar agentsTrial and failure of prior systemic or biologic therapies as specified per indication is required
    ProductPrior requirement before Stelara
    Stelara (ustekinumab)Member must have trial, intolerance, or contraindication to Yesintek or Steqeyma prior to coverage
    ContextDocumentation required
    Topical therapy requirement (e.g., plaque psoriasis)Documented trial and failure, contraindication, or intolerance to specified topical agents (examples listed: corticosteroids, vitamin D analogs, tazarotene, calcineurin inhibitors, anthralin, coal tar) before biologic approval when required
    Products / groupsPrerequisite Part D drug note
    Lynparza, Nexletol, Nexlizet, PCSK9-type entries (examples)Multiple products indicate criteria require use of a prerequisite Part D drug — the product-level line must be followed when present
    Xpovio and certain oncology supportive agentsSome oncology entries also note prerequisite Part D drug requirements for certain indications or combinations; follow item-specific language
    RequirementHow to demonstrate
    Document trial and failure, intolerance, or contraindication to listed agents prior to approval when requiredProvide medical record notes of prior medications and response, lab/imaging supporting intolerance/contraindication, or clinician attestation with rationale
    Examples: Voquezna H. pylori criteriaTrial and failure/intolerance/contraindication to bismuth quadruple therapy or two generic PPIs (as applicable) must be documented per indication-specific language

    Coverage Setting and Medicare Part Determination

    Billing Rule

    Medicare Part B vs Part D: submit setting

    This drug may be covered under Medicare Part B or Part D depending on the circumstances; include documentation of the use and setting to allow correct coverage assignment.

    • Possible settings include infusion center, office, hospital outpatient, or pharmacy.
    Billing Rule

    Office setting: document use and setting

    When requests involve office administration, providers must indicate the drug use and setting to support Part B/Part D determination and proper billing.

    Definitions and Key Terms

    Prerequisite Part D drug
    DefinitionA previously used Part D prescription agent that must be tried (or documented as contraindicated or intolerant) before coverage of the listed product is authorized.
    How appliedUsed as a step-therapy prerequisite for selected products (policy entries indicate 'Criteria DOES require use of a prerequisite Part D drug' where applicable).
    DocumentationProvider must document prior use, intolerance, or contraindication to the specified Part D agent when submitting prior authorization request.
    Rapidly progressing ADPKD
    DefinitionA diagnosis of autosomal dominant polycystic kidney disease demonstrating rapid progression, used as an eligibility requirement for Jynarque (tolvaptan) initial therapy.
    Required monitoring

    Background and Scope

    This partial extract lists numerous specialty and oral agents with product‑specific medical necessity rules used to adjudicate prior authorization requests. It emphasizes that providers must submit the documented diagnosis and supporting clinical information specified for each product (for example, mutation test results for CFTR modulators or oncology biomarkers), that many products require specialist prescribers or consultation, and that coverage determinations (including Part B vs Part D) and explicit exclusions are applied per the product entries.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyTufts Medicare Preferred Prior Authorization Medical Necessity Guidelines (partial drug list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documented diagnosis, required specialist prescriber attestation (when specified), and supporting clinical information per product.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaPrior Authorization, Documentation, and Denial RisksInitial Therapy RequirementsContinuation / Reauthorization RequirementsStep Therapy and Prerequisite Drug RequirementsCoverage Setting and Medicare Part DeterminationDefinitions and Key TermsBackground and Scope
    Lynparza prostate cancer: Deleterious or suspected deleterious germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer progressed following enzalutamide or abiraterone OR deleterious/suspected deleterious BRCA-mutated mCRPC used in combination with abiraterone and prednisone/prednisolone as specified

    Prescriber must be an oncologist; coverage duration 2 years.

    • For CF modulators and targeted oncology agents, include genotype/mutation test reports when required.
    • When the product notes a prerequisite Part D drug, document prior use, intolerance, or contraindication.
    • If a specialist prescriber is required, include that attestation or documentation of specialist consultation.
    Prior Authorization

    General prior authorization requirement — diagnosis and prescriber specialty

    Most products in this segment require prior authorization; documentation must include the specific diagnosis and prescriber specialty when indicated. Coverage durations are commonly specified (typically 2 years).

    • Verify the product entry for any additional documentation (e.g., prior therapy failure, lab values, imaging, biopsy).
    • Attach prescriber specialty credentials or consultation note when required.
    Prior Authorization

    Genotropin prior authorization — pediatric GHD initiation documentation

    For Genotropin (pediatric growth hormone initiation) submit radiographs showing open epiphyses, results of at least two standard GH stimulation tests, growth metrics (height >2 SD below mean), and documentation of the listed etiologies for short stature.

    • Prescriber should be an endocrinologist per the product entry.
    • Provide all specified test results and growth chart documentation with the request.
    Prior Authorization

    Product-specific prior authorization — include tests, prior therapy, and prescriber specialty

    Follow the product-specific prior authorization instructions for each drug: include the required diagnosis, prior therapies or failures, relevant test results (mutation/genotype where applicable), and prescriber specialty per the product entry.

    • Examples: CFTR mutation proof for CF modulators; FGFR2 fusion evidence for Pemazyre/Lytgobi; BRCA/HRR mutation reports for Lynparza.
    Prior Authorization

    Lynparza prior authorization — mutation status, prior therapy, oncologist prescriber

    Lynparza requests require prior authorization with documentation of deleterious or suspected deleterious gBRCA or HRR gene mutations, the prior lines of therapy applicable to the indication, and prescriber attestation that the prescribing physician is an oncologist; coverage duration is commonly 2 years.

    • For mCRPC use, document progression after enzalutamide or abiraterone when applicable.
    • If used in combinations (e.g., with abiraterone/prednisone), include treatment details per the indication.
    Prior Authorization

    Lytgobi prior authorization — FGFR2 fusion documentation and oncology prescriber

    For Lytgobi prior authorization submit documentation of a diagnosis of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements and attestation that the prescriber is an oncologist or consulted with one.

    • Coverage duration is noted as 2 years in the product entry.
    Prior Authorization

    PAH agents prior authorization — right heart catheterization confirmation and specialist prescriber

    PAH and CTEPH agents require prior authorization with documentation confirming the diagnosis by right heart catheterization (for PAH) or documentation of persistent/recurrent CTEPH post-surgical or inoperable status; the prescriber must be a cardiologist or pulmonologist.

    • Include the right heart catheterization report or surgical/inoperable documentation with the PAH request.
    • Coverage duration is commonly 2 years.
    Documentation Required

    Genetic/mutation documentation required — attach test reports

    When requested products depend on genetic or mutation status, include laboratory or genetic testing reports demonstrating the required mutation (for example, CFTR mutation for Orkambi/Trikafta/Kalydeco; BRCA/HRR status for Lynparza; IDH1 for Tibsovo).

    • If genotype is unknown for CFTR modulators, submit an FDA‑cleared CF mutation test and verification sequencing when indicated.
    • For oncology targeted therapies, attach the molecular pathology or genomic testing report.
    Documentation Required

    Transplant documentation required — confirm transplant type and CMV risk

    When a product's criteria reference post‑transplant CMV risk or transplant status (e.g., Prevymis, Livtencity), submit documentation of the transplant (allogeneic HSCT or kidney transplant) and evidence the member is at risk for or has CMV infection/disease.

    • Include transplant type, date, and any relevant virology/genotypic resistance testing for CMV as applicable.
    Documentation Required

    NASH staging documentation required for Rezdiffra — fibrosis F2–F3 confirmation and metabolic risk

    For Rezdiffra (MASH/NASH) initial authorization submit non-cirrhotic disease documentation with fibrosis stage F2–F3 confirmed by the specified biomarker/imaging or a liver biopsy within the past 12 months, plus at least one metabolic risk factor (e.g., T2DM, hypertension, obesity).

    • Provide the specific biomarker and imaging results (e.g., ELF, FIB‑4, FibroScan, MRI‑PDFF) or liver biopsy report used to stage fibrosis.
    Prior Authorization

    Rydapt prior authorization — FLT3+ AML documentation and prescriber specialty

    Rydapt prior authorization requires documentation that AML is FLT3 mutation‑positive when used as first‑line therapy in combination with standard cytarabine/daunorubicin induction and cytarabine consolidation; the prescriber must be a hematologist/oncologist or allergist.

    • Do not submit Rydapt for single‑agent induction AML use — the product entry excludes single‑agent induction.
    • Include FLT3 mutation testing report and treatment plan showing combination induction/consolidation.
    Prior Authorization

    Skyrizi prior authorization — indication-specific diagnosis and specialist prescriber

    Skyrizi prior authorization requests must include the indication‑specific diagnosis (e.g., moderate‑to‑severe plaque psoriasis with prior topical failure, psoriatic arthritis, Crohn's disease, ulcerative colitis) and documentation that the prescriber is a dermatologist, rheumatologist, or gastroenterologist as appropriate.

    • For plaque psoriasis, include documentation of prior topical therapy failure as specified.
    • Coverage duration is typically 2 years per the product entry.
    Prior Authorization

    Prior authorization and specialty prescriber — include specialist attestation or consult

    When a product requires a specialist prescriber, include the specialist's attestation or consultation note with the prior authorization (examples: oncologist for many targeted agents; pulmonologist or CF center specialist for CF therapies).

    • If the product entry names the required prescriber type, the request should show the prescriber meets that requirement or that a specialist consultation has occurred.
    Step Therapy

    Prior authorization and prerequisite Part D therapy — document prior Part D drug use or intolerance

    If the product's criteria specify prerequisite Part D therapy or 'Criteria DOES require use of a prerequisite Part D drug', document prior use, intolerance, or contraindication to the named Part D agent(s) before approval.

    • Examples include Lynparza, Nexletol/Nexlizet, Piqray and others that explicitly require prior Part D drug use.
    • Attach medication history, pharmacy fill records, or prescriber attestation of intolerance/contraindication.
    Billing Rule

    Part B vs Part D determination — provide use and setting details

    When the drug may be covered under Medicare Part B or Part D depending on use and setting, submit information describing the drug's use and the clinical setting to allow correct Part B vs Part D determination.

    • Include administration site (office, infusion center, hospital outpatient, pharmacy), and whether the drug is administered incident to a physician service or as an outpatient prescription.
    Step Therapy

    Prerequisite therapy / step requirements — document trials and failures or attestations

    Document trial and failure, contraindication, or intolerance to specified conventional or topical therapies when the product's criteria list step therapy requirements (examples: RA agents, certain biologics, topical therapies for psoriasis).

    • Provide dates, doses, and reasons for discontinuation (lack of response, adverse effects, contraindication) or attestation that trials are clinically inappropriate.
    • For rheumatologic indications, detail TNF inhibitor trials and conventional DMARD trials when required.
    Step Therapy

    Step therapy / prerequisite therapy requirements — evidence of required Part D trials

    For specific step therapy rules where the product indicates 'Criteria DOES require use of a prerequisite Part D drug' (e.g., Fasenra, Ibrance, Lynparza in some entries), include evidence of the required prior Part D medication trial or a clinician attestation of contraindication/intolerance.

    • Attach pharmacy fill records, medication administration records, or prescriber statement indicating prior use and outcome.
    Step Therapy

    Fasenra step therapy — document prerequisite Part D drug use or attestation

    Fasenra requests require documentation that the member has used the prerequisite Part D drug(s) indicated by the product entry, or provide a prescriber attestation that trials are inappropriate.

    • Include prior medication history for inhaled corticosteroids plus additional controller trials as noted in the Fasenra entry when applicable.
    Step Therapy

    Ibrance step therapy — document prerequisite Part D drug use

    Ibrance prior authorization requires documentation of the prerequisite Part D drug use when the product's criteria indicate 'Criteria DOES require use of a prerequisite Part D drug'; include prior endocrine or other indicated therapies as appropriate.

    • Attach medication history or pharmacy fill records showing prior therapy trials or prescriber attestation if trials are inappropriate.
    Step Therapy

    Kineret RA prerequisite therapy — document two alternative therapy trials or attestation

    For Kineret (anakinra) in RA initial therapy, document trial and failure, intolerance, or contraindication to two specified alternatives (examples: Enbrel, a formulary adalimumab product, Orencia, Rinvoq, Xeljanz) or provide an attestation that trials are inappropriate; prescriber should be or consult a rheumatologist.

    • Include dates and reasons for discontinuation of the two alternatives or a prescriber's rationale for bypassing trials.
    Step Therapy

    Therapy trial/failure required — submit prior therapy history and failure rationale

    When the product entry requires documentation of a trial/failure of prior therapies (e.g., Rezurock, Rinvoq, Rezlidhia), submit records showing prior systemic or biologic therapy trials and the clinical rationale for failure or intolerance.

    • Include prior medication names, durations, doses, clinical response, and adverse events leading to discontinuation.
    Step Therapy

    Stelara step requirement — document trial/failure of Yesintek or Steqeyma

    Stelara prior authorization requires documentation that the member has trialed and had intolerance/contraindication or failure of Yesintek or Steqeyma before approving Stelara for specified indications.

    • Provide dates and clinical response to the preferred agents or prescriber attestation of contraindication/intolerance.
    Step Therapy

    Skyrizi prerequisite therapy — document prior Part D drug trials or attestation

    For Skyrizi, where criteria indicate a prerequisite Part D drug is required for some indications, document prior use, intolerance, or contraindication to the listed Part D therapy or provide a prescriber attestation.

    • Include prior topical or systemic therapy trials for plaque psoriasis as specified when applicable.
    Step Therapy

    Step/step-like therapy requirements — show prior therapy trials and outcomes

    Several products require step or step‑like therapy: document trials and failures, intolerances, or contraindications to the specified prior therapies (e.g., TNF inhibitors, conventional DMARDs, topical agents, PPIs) before approval.

    • Attach clinical notes, pharmacy fills, or prescriber attestations showing prior therapy attempts and outcomes.
    Step Therapy

    Failure of prior therapies required for rheumatologic indications — document TNF and DMARD history

    For rheumatologic indications requiring failure of prior therapies (e.g., ankylosing spondylitis, RA, psoriatic arthritis), document inadequate response or intolerance to TNF inhibitors and/or conventional therapies as specified in the product entry.

    • Provide treatment history including agents, duration, and reasons for discontinuation or inadequate response.
    Documentation Required

    Required medical information — attach documented diagnosis and disease-specific support

    Providers must supply the documented diagnosis and the supporting disease‑specific medical information per product (examples: CF genotype for CFTR modulators; mutation status for targeted oncology agents; confirmation of PAH by right heart catheterization).

    • Include laboratory, imaging, pathology, or genetic testing reports referenced in the product entry.
    Documentation Required

    Required diagnosis documentation for medullary thyroid cancer agents — progressive/metastatic disease proof

    For medullary thyroid cancer agents (e.g., Cometriq, Cabozantinib), include documentation of progressive or metastatic medullary thyroid cancer (unresectable locally advanced or metastatic disease) and, when specified, that an oncologist is the prescriber.

    • Attach imaging, pathology, and oncologist treatment notes supporting the progressive/metastatic diagnosis.
    Documentation Required

    Required infection documentation — provide culture or microbiology evidence

    For infections related to specific products (example: Cayston), include documentation of the infection—e.g., diagnosis of cystic fibrosis and evidence of Pseudomonas aeruginosa in the lungs.

    • Attach respiratory culture reports or clinical microbiology evidence demonstrating Pseudomonas aeruginosa.
    Documentation Required

    Dupixent required medical information — include indication-specific trials and phenotype data

    Dupixent prior authorization must include the indication‑specific documentation such as trial and failure of topical agents for atopic dermatitis, eosinophilic phenotype data for asthma, or inadequate control of CRSwNP—also note the prescriber specialty or consultation.

    • Attach trial documentation for prior topical/systemic therapies, eosinophil counts, or ENT documentation for nasal polyps where applicable.
    Documentation Required

    Diagnosis documentation (examples) — attach specialty notes and diagnostic findings

    Provide diagnosis documentation examples per product entries (e.g., partial‑onset seizures with TSC for Exkivity-type entries; SEGA not a surgical candidate) when applicable to the requested therapy.

    • Include neurologist or neurosurgeon notes confirming surgical candidacy or epilepsy diagnosis details.
    Documentation Required

    Inqovi documentation — MDS subtype and IPSS risk group required

    For Inqovi requests, include the documented diagnosis of MDS with the specified FAB subtypes and IPSS risk grouping as required by the product entry.

    • Attach hematopathology reports, bone marrow biopsy results, and IPSS risk calculation documentation.
    Documentation Required

    Indication-specific diagnosis — include prior therapy history and specialist confirmation

    Ensure indication‑specific diagnosis documentation is attached (examples: chronic GVHD after failure of one or two lines for Jaypirca; intermediate or high‑risk myelofibrosis for myelofibrosis indications).

    • Provide prior therapy details and specialist notes confirming the indication and prior treatment history.
    Documentation Required

    Genotype documentation for Kalydeco — attach CFTR mutation test and verification

    For Kalydeco (ivacaftor), submit documentation of a CFTR mutation responsive to the drug based on clinical and/or in vitro assay data or an FDA‑cleared mutation test result with sequencing verification when indicated.

    • If genotype is unknown, include an FDA‑cleared CF mutation test and follow testing instructions for sequencing when recommended.
    Documentation Required

    Lynparza required medical information — BRCA/HRR mutation reports and prior therapy documentation

    For Lynparza, include documentation of deleterious or suspected deleterious germline BRCA or HRR gene mutations, prior lines of therapy relevant to the indication (chemotherapy, endocrine therapy where applicable), and the treatment setting (neoadjuvant/adjuvant/metastatic) as applicable.

    • Attach genetic testing reports (germline and/or somatic) and clinical oncology treatment history to the PA request.
    Documentation Required

    PAH documentation — submit right heart catheterization/hemodynamic confirmation

    PAH therapy requests must include documentation confirming PAH by right heart catheterization or documentation that CTEPH is persistent/recurrent post‑surgical or inoperable.

    • Attach hemodynamic data (mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output) from the catheterization report.
    Documentation Required

    Orkambi required medical information — F508del homozygosity and CF diagnosis

    For Orkambi (CF), include documentation that the member is homozygous for the F508del CFTR mutation and has a diagnosis of cystic fibrosis.

    • Attach CFTR genetic testing demonstrating homozygous F508del and clinical CF diagnosis notes.
    Documentation Required

    Otezla required medical information — diagnosis and prior topical therapy evidence

    For Otezla, include the documented diagnosis appropriate to the indication (psoriatic arthritis, plaque psoriasis with prior topical failures, Behcet's with active oral ulcers) and prescriber specialty where required.

    • Attach prior topical therapy trial documentation for plaque psoriasis when applicable.
    Documentation Required

    Pemazyre required medical information — FGFR alteration testing and prior therapy

    Pemazyre prior authorization requires documentation of FGFR2 fusion for cholangiocarcinoma or FGFR1 rearrangement for MLNs and prior treatments where specified; include the oncologist's notes and molecular testing reports.

    • Attach pathology and molecular assay reports confirming FGFR2/FGFR1 alterations and prior therapy records.
    Documentation Required

    PCSK9 inhibitors required medical information — LDL levels, statin history, and diagnosis confirmation

    For PCSK9 inhibitors (Praluent/Repatha), submit documentation of elevated LDL‑C on high‑intensity statin therapy or statin intolerance, and the diagnosis (ASCVD, HeFH, HoFH) with genetic or clinical confirmation as applicable.

    • Include lipid panels, statin regimen details, and genetic testing or clinical criteria supporting familial hypercholesterolemia when required.
    Documentation Required

    Tibsovo required information — IDH1 mutation and treatment setting documentation

    For Tibsovo, include the documented diagnosis and susceptible IDH1 mutation status and specify the treatment setting (relapsed/refractory AML, newly diagnosed when ineligible for intensive induction, cholangiocarcinoma, or MDS).

    • Attach molecular testing confirming IDH1 mutation and clinical notes documenting line of therapy and eligibility for intensive induction.
    Documentation Required

    Trikafta required information — CF diagnosis, responsive CFTR mutation, and age-specific formulation

    For Trikafta, include documentation of cystic fibrosis diagnosis and CFTR mutation responsive to the therapy; indicate age‑appropriate formulation (granules for 2 to <6 years; tablets for ≥6 years) and a pulmonologist or CF center specialist as prescriber or consultant.

    • Attach CFTR genetic testing and pediatric age documentation when applicable.
    • For reauthorization, provide evidence of clinical response (e.g., ppFEV1 improvement or fewer pulmonary exacerbations).
    Documentation Required

    Required documentation — include mutation status, prior therapy, and specialist notes

    Providers must submit the documented diagnosis and all supporting disease‑specific information required by the product entry (e.g., mutation status, prior endocrine therapy, PIK3CA/AKT1/PTEN alteration reports for Tukysa).

    • Include molecular pathology, prior treatment history, and specialist consultation notes as applicable.
    Documentation Required

    Required clinical documentation — diagnosis, prior therapies, and molecular markers

    Submit required clinical documentation showing the specific diagnosis, prior treatment history, and molecular marker status when applicable (examples: ALK, ROS1, BRAF V600; prior therapy failures).

    • Attach pathology, genomic testing reports, treatment timelines, and prescriber specialty attestations.
    Billing Rule

    Submit drug use and setting information — required for Part B vs Part D determination

    Include information describing the drug's use and setting to determine Medicare Part B versus Part D coverage (e.g., administration in infusion center or as an outpatient pharmacy fill), as failure to submit this may delay processing.

    • Specify site of care (office, infusion center, hospital outpatient, pharmacy) and whether administration is physician‑administered or self‑administered.
    Denial Risk

    Denial triggers from listed exclusions — verify indication against exclusions

    Requests for uses explicitly excluded in the product entries will be denied; verify the indication against product exclusions prior to submission (examples: modafinil/armodafinil not for generalized fatigue/jet lag; Dupixent not for acute bronchospasm).

    • Check product-level exclusion lists in the policy before submitting a PA request.
    • Do not submit PA for indications explicitly stated as not covered.
    Denial Risk

    Dupixent explicit denial risk — not for acute bronchospasm/status asthmaticus

    Dupixent will not be approved for relief of acute bronchospasm or status asthmaticus; do not submit prior authorization for these excluded uses.

    • Ensure the documented indication is one of the covered Dupixent indications before requesting authorization.
    Denial Risk

    Icatibant exclusion — acquired angioedema or concurrent ACE inhibitor use

    Icatibant is excluded for members with acquired angioedema or for those concurrently taking an ACE inhibitor; such requests will not be approved.

    • Confirm HAE type and concomitant medications before submitting a prior authorization request for Icatibant.
    Denial Risk

    Iclusig exclusion — not for newly diagnosed chronic phase CML

    Iclusig will not be approved for members with newly diagnosed chronic‑phase CML; ensure the diagnosis and disease phase meet the product criteria before submission.

    • For CML requests, include disease phase and prior kinase inhibitor history as indicated.
    Documentation Required

    Jynarque liver monitoring and history — baseline and scheduled liver tests required

    For Jynarque initial therapy, ensure baseline and scheduled liver tests (ALT, AST, bilirubin) are documented per the duration‑based schedule and confirm the member does not have a history of significant liver impairment; absence of required liver monitoring or a disqualifying liver history may preclude authorization.

    • If patient has received Jynarque ≤18 months, document tests prior to initiation, at 2 and 4 weeks, then monthly for first 18 months; if >18 months on therapy, document testing at least every 3 months.
    • Document absence of significant prior liver injury (excluding uncomplicated polycystic liver disease).
    Denial Risk

    Lynparza denial risk — missing mutation status or prior therapy documentation may cause denial

    Lack of documented BRCA/HRR mutation status, prior therapies, or relevant treatment setting for Lynparza may trigger denial; include genetic test reports and prior oncology treatment history when submitting a PA for Lynparza.

    • Attach germline/somatic BRCA or HRR testing and oncology notes showing prior chemotherapy/endocrine therapy as applicable.
    Denial Risk

    PAH products denial risk — absence of right heart catheterization confirmation

    PAH product requests lacking right heart catheterization confirmation of PAH risk denial; submit the invasive hemodynamic confirmation to avoid denial.

    • Include the catheterization report with measured hemodynamics supporting the PAH diagnosis.
    Denial Risk

    Explicit exclusion denial risk — do not submit for excluded indications (e.g., quinine for leg cramps)

    Coverage will not be approved for indications explicitly excluded (example: quinine sulfate for nocturnal leg cramps); do not request authorization for excluded indications.

    • Review the product's exclusion statement before submitting any PA request to avoid an expected denial.
    Denial Risk

    Rubraca concurrent therapy exclusion — ensure non-concurrent use with chemotherapy

    Rubraca will not be approved for concurrent use with other chemotherapy agents; when requesting maintenance Rubraca, ensure the request documents that it will not be given concurrently with other chemotherapy.

    • Include current chemotherapy status and planned treatment regimen to demonstrate non‑concurrent use.
    Denial Risk

    Rydapt treatment modality exclusion — not for single-agent induction AML

    Rydapt will not be approved as single‑agent induction therapy for AML; when requesting Rydapt for AML, document the appropriate combination induction and consolidation regimen or other approved indication.

    • Attach treatment plan and FLT3 mutation testing supporting use in combination induction.
    Denial Risk

    Tadalafil explicit exclusion — not covered for erectile dysfunction

    Tadalafil is excluded from coverage for the treatment of erectile dysfunction; ensure requests for tadalafil are for covered indications (e.g., BPH with specified prior therapy failure) as described in the policy.

    • If requesting tadalafil for BPH, include documentation of prior trials/failures of specified BPH medications per the product entry.
    Denial Risk

    TIRF exclusion — only for breakthrough cancer pain in opioid‑tolerant patients

    Transmucosal Immediate‑Release Fentanyl (TIRF) products will not be covered for any non‑cancer pain indication; submit PA only for management of breakthrough cancer pain in opioid‑tolerant adult cancer patients and document opioid tolerance.

    • Document opioid tolerance (examples provided in the policy) and confirm patient remains on around‑the‑clock opioids while using TIRF.
    • Lozenges approvable for pediatric patients 16 years and older only per the product entry.
    Denial Risk

    Documentation-based denials — include all required diagnostic and prescriber documentation

    Requests that lack required diagnostic documentation (e.g., CF genotype for CFTR modulators; documented PIK3CA/AKT1/PTEN alterations for Tukysa) or that are missing required specialist prescriber restrictions may be denied; ensure all specified diagnostic and prescriber documentation is attached.

    • Review the product entry checklist and attach molecular testing, pathology, and specialist consultation notes as required.
    Denial Risk

    Lack of documented diagnosis — confirm and attach indication-specific diagnostic evidence

    Requests may be denied if the member does not have the documented diagnosis required for the specific drug (examples: von Hippel‑Lindau disease for Wyost indications, ALK‑positive NSCLC for Xalkori). Verify and attach diagnosis documentation.

    • Attach disease‑specific diagnostic reports (e.g., genetic testing, pathology, imaging) supporting the covered indication.
    Billing Rule

    Missing Part B/Part D use/setting information — include administration site and use details

    Failure to submit information describing the use and setting of the drug may prevent determination of Medicare Part B versus Part D coverage and could delay processing; include site‑of‑care and administration details with the prior authorization.

    • Specify whether the drug is physician‑administered (office/infusion/hospital outpatient) or dispensed as a pharmacy benefit, and include related treatment notes.
    Note
    Note
    Note
    If on Jynarque ≤18 months: ALT, AST, and bilirubin measured prior to initiation, at 2 and 4 weeks after initiation, then monthly for first 18 months; if >18 months: measured at least every 3 months.
    Contraindication notePatient must not have history of significant liver impairment or injury (excluding uncomplicated polycystic liver disease).
    Kalydeco-responsive CFTR mutation
    DefinitionA CFTR gene mutation demonstrated to be responsive to ivacaftor (Kalydeco) based on clinical and/or in vitro assay data or identified by an FDA-cleared CF mutation test.
    Genotype testingIf genotype unknown, use an FDA-cleared cystic fibrosis mutation test and follow with verification sequencing when recommended by the test instructions for use.
    Age/formulation noteFor Kalydeco granules: patient age ≥1 month (other CFTR modulators list age-specific formulation limits separately).
    deleterious or suspected deleterious BRCA/HRR mutation
    DefinitionA deleterious or suspected deleterious germline or somatic BRCA or homologous recombination repair (HRR) gene mutation documented in the member's medical record, required to qualify for Lynparza (olaparib) indications.
    Required documentationProvider must submit evidence of deleterious or suspected deleterious gBRCA or HRR mutation status and prior lines of therapy or treatment setting as applicable to the indication.
    Applies toMultiple tumor settings including breast, ovarian, pancreatic, and prostate cancer per Lynparza criteria.
    right heart catheterization-confirmed PAH
    DefinitionPulmonary arterial hypertension (PAH) confirmed by right heart catheterization — hemodynamic confirmation required for coverage of PAH therapies.
    Alternative diagnosisChronic thromboembolic pulmonary hypertension (CTEPH) eligibility requires documented persistent/recurrent CTEPH after surgical treatment or inoperable disease.
    Prescriber requirementPrescribing physician must be a cardiologist or pulmonologist for PAH/CTEPH agents.
    MASH
    DefinitionMetabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
    Diagnostic criteria (example)Initial authorization requires non-cirrhotic disease with fibrosis stage F2 or F3 confirmed by specified serum and imaging biomarkers or liver biopsy, plus ≥1 metabolic risk factor (e.g., type 2 diabetes, hypertension, obesity).
    PrescriberPrescribed by or in consultation with a gastroenterologist or hepatologist for Rezdiffra (MASH/NASH).
    Coverage Duration
    Typical durationAuthorization period commonly set to 2 years for most products in this segment.
    ExceptionsSome products list different durations (examples: Rezdiffra reauthorization and certain short-course therapies); Jynarque initial coverage noted as 1 year in chunk 57 for ADPKD initial criteria.
    Use for reauthorizationReauthorization often requires demonstration of positive clinical response (e.g., stability, improved symptoms, or no progression to cirrhosis) per product-specific rules.
    Trial and failure (TF)
    DefinitionTrial and failure (TF): the member has had an inadequate response, intolerance, or contraindication to a specified prior therapy as listed in the product-specific criteria.
    Evidence requiredProvider must document prior therapy trials, reasons for failure/intolerance/contraindication, or attest that trials are clinically inappropriate when submitting prior authorization.
    Common applicationsUsed in step-therapy requirements for rheumatologic, GI, dermatologic, and oncology-sparing indications where prior systemic or biologic therapies are specified.
    Prerequisite Part D drug (duplicate)
    DefinitionA previously used Part D medication that must have been used before the requested product will be authorized; similar to 'Prerequisite Part D drug'.
    Policy noteSeveral product entries explicitly indicate whether criteria 'DOES require use of a prerequisite Part D drug' or 'DOES NOT require' — follow the product-specific indication text.
    Provider actionDocument prior Part D drug use or provide rationale for inappropriateness when requested for prior authorization review.
    Part B versus Part D
    DefinitionDetermination of whether a drug is covered under Medicare Part B or Part D depends on the drug's use, administration route, and site/setting of care.
    Required informationInformation describing the use and setting of the drug must be submitted to make the Part B vs Part D determination (e.g., administered in physician office/infusion center vs outpatient pharmacy dispensation).
    ImpactFailure to submit use/setting information may prevent correct assignment and delay coverage processing.